{"id":254574,"title":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) - Summary - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T13:20:09.969000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100.html","snippet":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) - Summary - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search…","rawSnapshotUrl":"/api/snapshots/raw/254574","browseUrl":"https://replay.healtharchive.ca/job-1/20250418132009/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100.html#ha_snapshot=254574","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}